carboxyamido-triazole has been researched along with paclitaxel in 3 studies
Studies (carboxyamido-triazole) | Trials (carboxyamido-triazole) | Recent Studies (post-2010) (carboxyamido-triazole) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
---|---|---|---|---|---|
105 | 15 | 22 | 31,874 | 5,729 | 15,395 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, PS | 1 |
Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A | 1 |
Azad, N; Figg, WD; Gardner, E; Graves, C; Imamura, CK; Kohn, EC; Kotz, H; Minasian, L; Perroy, A; Raggio, M; Sarosy, GA | 1 |
2 trial(s) available for carboxyamido-triazole and paclitaxel
Article | Year |
---|---|
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Middle Aged; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors; Treatment Outcome; Triazoles; Tumor Cells, Cultured | 2001 |
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome; Triazoles; Young Adult | 2009 |
1 other study(ies) available for carboxyamido-triazole and paclitaxel
Article | Year |
---|---|
Biotechnology transfer at the National Institutes of Health.
Topics: Aminoimidazole Carboxamide; Antineoplastic Agents; Biotechnology; Ethics, Medical; Humans; Industry; National Institutes of Health (U.S.); Paclitaxel; Proteins; Research; Research Support as Topic; Technology Transfer; Tissue Inhibitor of Metalloproteinase-2; Triazoles; United States | 1993 |